Study Immunotherapy and Chemotherapy Before Colon Surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests immunotherapy plus chemotherapy given before surgery for colon cancer that hasn’t spread. It aims to shrink or control the tumor and improve outcomes in people whose tumor has certain immune/biologic features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign consent and follow the study plan.
- Your colon tumor is confirmed to be resectable (can be surgically removed) and non-metastatic (no distant spread).
- Your tumor test shows MSS or pMMR (based on lab testing at the study site).
- Tumor is at least 12 cm above the anus (so it’s not treated like a rectal cancer).
- You have at least one “high-risk” feature (like higher CEA, certain lab ratios, or specific scan/pathology findings).
- Your general health and blood/organ tests meet study limits (including good performance status 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two chemotherapy drugs (CAPOX) plus an immunotherapy drug (tislelizumab) before surgery for high-risk colon cancer that has not spread. It aims to see if adding tislelizumab helps shrink the tumor and lower the chance of the cancer coming back.
This Phase 2 trial studies giving chemotherapy plus immune therapy before surgery for certain colon cancers that do not have mismatch repair defects (MSS/pMMR). The goal is to shrink and control the tumor and improve outcomes compared with standard approaches.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests a combination of an immunotherapy drug (PD-1 antibody), two types of immune-boosting drugs (rhG-CSF and IL-2), and chemotherapy (CapeOX) given before surgery for colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and improve outcomes, and it is designed for patients whose cancer can be surgically removed.
This trial tests whether giving chemotherapy before surgery can improve outcomes for patients with colon cancer that has not spread to other parts of the body. The treatment aims to shrink the tumor and reduce the chance of the cancer coming back.
This trial compares two different chemotherapy combinations given before surgery for locally advanced colon cancer. One option adds an immunotherapy drug to the chemo. The goal is to see which approach works better at shrinking the tumor and improving outcomes.
Hear when a new Stage I Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.